How Is Chronic Lymphocytic Leukemia Treated?

This content has been reviewed and approved by

Hagop M. Kantarjian, MD
Chairman & Professor, Leukemia Department
MD Anderson Cancer Center
University of Texas
 

In the early stages, chronic lymphocytic leukemia (CLL) may not need treatment and you may be only observed. Many patients may live their normal life span not needing any treatment. Treatment is generally advised in patients with advanced CLL (Rai stage III-IV), if there is bulky disease (lymph nodes, liver spleen), if they have complications of CLL (infections, immune problems), or if they have significant symptoms caused by CLL, such as fatigue, sweats, fever, weight loss, severe skin itching/lesions, or others.

Specific treatment for CLL will be determined by your physician based on:

  • Your age, overall health, and medical history
  • Extent of the disease
  • Stage of the disease
  • Your tolerance for specific medications, procedures, or therapies
  • Expectations for the course of the disease
  • Your opinion or preference
Treatment may include:
  • Chemotherapy
  • Monoclonal antibodies (Rituxan® [rituximab] or Campath® [alemtuzumab]
  • Treatment for complications, such as infection or anemia
  • Bone marrow transplantation
  • Splenectomy - surgery to remove the spleen
  • Radiation therapy
This content was last modified on August 11, 2007 .
Latest Chronic Lymphocytic Leukemia News
Hair dye may boost lymphoma risk: study

June 13, 2008 — NEW YORK (Reuters Health) - A new study suggests that use of hair dye may increase the risk of certain types of non-Hodgkin lymphoma (NHL), a blood cancer involving the lymph nodes.

Cephalon wins U.S. approval for leukemia drug

March 21, 2008 — WASHINGTON (Reuters) - Cephalon Inc won U.S. approval to sell a chemotherapy drug to treat patients with a slow-growing type of leukemia, the company said on Thursday.

Experimental drug works in type of leukemia

December 10, 2007 — NEW YORK (Reuters) - Cephalon Inc's experimental cancer drug Treanda was significantly more effective than a common chemotherapy agent in helping patients with chronic lymphocytic leukemia (CLL) who had not received prior treatment achieve remission, according to a late-stage study.

Select news items provided by Reuters Health